Hims & Hers Introduces Peptides+ Specialty to Expand Clinically Guided Access to Peptide Therapies
Company prepares to offer personalized peptide-based treatments as U.S. regulators consider a pathway for compounding selected peptides
Hims & Hers is preparing to expand its presence in personalized healthcare with the introduction of Peptides+, a new specialty focused on peptide-based treatments and other therapies being explored for potential health and wellness applications. The announcement comes as the U.S. Department of Health and Human Services (HHS) moves toward allowing the compounding of six peptides under a draft interim policy while formal rulemaking continues. The development represents a potentially important step in the ongoing discussion about how certain peptide therapies may be accessed through regulated healthcare channels.
The company said its approach will emphasize clinical oversight, individualized treatment plans, quality standards, and transparency. These elements are particularly important in a specialty where scientific understanding of many compounds remains limited and consumer interest has grown. Hims & Hers aims to establish a structured care model that allows eligible customers to explore certain therapies under the supervision of independent healthcare providers, with treatments supplied through licensed pharmacies.
Peptides+ is being developed around a clinically guided approach intended to account for individual health and wellness goals. According to the company, the specialty will explore treatment options associated with areas such as energy, recovery, cognitive clarity, and cellular resilience. However, the company also acknowledges that research into many of these compounds is still developing, and the evidence supporting their potential applications varies.
The planned introduction of Peptides+ reflects a broader trend toward personalized healthcare services, in which treatment decisions are increasingly organized around individual needs rather than a single approach intended for everyone. At the same time, the launch highlights the importance of distinguishing emerging therapeutic possibilities from established clinical evidence.
Regulatory developments create potential opportunities for peptide compounding
The planned launch comes amid changing regulatory discussions surrounding compounded peptide products in the United States. According to Hims & Hers, HHS recently moved to allow compounding of six peptides while formal rulemaking is underway, following recommendations made by the Pharmacy Compounding Advisory Committee (PCAC) earlier in the summer.
This development could influence how selected peptide compounds are considered for use in compounded medications. However, the precise regulatory status of individual substances remains important, and a draft interim policy should not be interpreted as blanket approval for every peptide or every proposed medical use.
Compounding generally involves preparing a medication for an individual patient when certain conditions justify a formulation different from a commercially available, approved drug. Compounded medications are not the same as FDA-approved drugs, and their availability is subject to applicable federal and state requirements. For that reason, the ability to compound a particular substance depends on its regulatory classification, the circumstances of its use, and the rules that apply at the time.
The discussion surrounding peptide compounding has attracted attention as consumers and healthcare professionals seek greater clarity about the availability, quality, and appropriate use of these substances. Peptides are compounds made up of amino acids, and they play different roles in biological processes. Some peptide-based medicines have established medical uses, while other compounds marketed for wellness or performance-related purposes remain under investigation.
This distinction is central to the emerging peptide market. A compound’s biological activity or popularity does not automatically demonstrate that it is safe and effective for a particular purpose. Scientific evidence, appropriate clinical evaluation, manufacturing quality, and regulatory compliance remain important considerations when determining whether a treatment should be used.
Hims & Hers views the latest policy development as a potential move toward a more structured environment for selected peptide therapies. The company argues that regulated channels can provide greater safeguards than informal sources, where customers may have limited information about product quality, ingredient identity, preparation methods, or the circumstances under which a substance should be used.
Nevertheless, the regulatory process is ongoing. Further decisions, guidance, or changes to applicable rules may affect which compounds can be offered and under what conditions. Hims & Hers said it intends to continue monitoring these developments as it prepares its new specialty.
Peptides+ focuses on personalized healthcare
Peptides+ is intended to bring peptide-related treatment options into a more organized healthcare framework. Rather than offering a uniform treatment to every customer, the specialty is designed to support personalized plans based on individual eligibility and clinical assessment.
According to Hims & Hers, customers who qualify may receive a treatment plan prescribed by independent healthcare providers. Treatments will be supplied by licensed pharmacies, while ongoing clinical support is intended to help customers navigate their care.
This model places the prescribing decision with healthcare professionals rather than relying solely on consumer demand. The approach is particularly relevant for emerging therapies because the benefits, risks, and appropriate uses of some compounds are not yet fully understood.
Individualized treatment planning may involve considering a person’s health history, current medications, symptoms, treatment objectives, and other relevant clinical factors. The exact evaluation required will depend on the specific compound and the treatment being considered. Eligibility for one therapy would not necessarily establish eligibility for another.
The company said Peptides+ is designed to account for the fact that individual biology can change over time. This reflects the broader principle behind personalized healthcare: treatment decisions should be guided by a person’s circumstances and medical needs, with adjustments made when clinically appropriate.
However, personalization does not remove the need for evidence-based prescribing. Even when a treatment plan is tailored to an individual, its use must still be considered in light of available research, known risks, potential interactions, and applicable regulatory requirements.
For Hims & Hers, the challenge will be to combine consumer accessibility with appropriate clinical safeguards. As interest in peptide-based products continues, the company is positioning Peptides+ as an effort to establish a more transparent and professionally supervised route for eligible customers.
Planned treatment options include several compounds
Hims & Hers plans to introduce access to several compounds through Peptides+, subject to eligibility and applicable requirements. The initial list announced by the company includes Sermorelin, Glutathione, vitamin B12, NAD+, and L-carnitine. The company said BPC-157 and TB-500 could be added later when permitted.
The compounds on the proposed list differ in their biological functions, levels of scientific evidence, and regulatory considerations. They should not be treated as interchangeable therapies, and the fact that they are included in a planned specialty does not mean that all have the same evidence base or approved indications.
Sermorelin
Sermorelin is a peptide associated with the body’s growth hormone-releasing pathway. It has been discussed in clinical and wellness settings because of its relationship to the regulation of growth hormone. Its potential use requires careful consideration of the relevant medical context, including the person’s health status and the evidence supporting a particular treatment objective.
The existence of a biological mechanism does not, by itself, establish that a therapy will deliver specific benefits such as improved recovery, increased energy, or changes in body composition. Clinical decisions should be based on the applicable evidence and the individual’s circumstances.
Glutathione
Glutathione is a naturally occurring antioxidant involved in cellular processes, including the management of oxidative stress. It has attracted interest in wellness discussions because of its role in normal cellular function.
However, the benefits of using supplemental or compounded glutathione can depend on the formulation, route of administration, dose, and intended purpose. Claims about specific wellness outcomes should be evaluated carefully, and the compound’s normal biological role should not be confused with proof that a particular treatment improves health in every setting.
Vitamin B12
Vitamin B12 is an essential nutrient involved in red blood cell formation, neurological function, and DNA synthesis. It is an established component of medical care for people who have a deficiency or certain conditions that interfere with absorption.
The clinical value of supplementation depends on factors such as a person’s nutritional status, medical history, and the reason treatment is being considered. For individuals without a deficiency or another clinical indication, additional supplementation may not provide the same benefits as it does for those who need it.
NAD+
Nicotinamide adenine dinucleotide, commonly known as NAD+, is a molecule involved in cellular energy metabolism and other biological processes. It has become a focus of research and consumer interest related to aging, metabolism, and cellular function.
Despite this interest, evidence supporting specific NAD+-based interventions for a wide range of wellness outcomes remains an evolving area of research. Claims relating to longevity, cognitive performance, or improved energy require appropriate clinical evidence rather than relying solely on the molecule’s role in normal cellular processes.
L-carnitine
L-carnitine is a compound involved in transporting fatty acids into mitochondria, where they can be used in energy production. It is found in the body and can also be obtained through dietary sources or supplements.
Its clinical relevance varies by individual and medical context. The potential effects of a treatment may depend on whether a person has a deficiency, an underlying health condition, or another reason for its use. General claims about energy, exercise performance, or recovery should not be interpreted as guaranteed outcomes.
BPC-157 and TB-500
Hims & Hers has also identified BPC-157 and TB-500 as possible future additions, subject to applicable regulatory requirements.
These compounds have attracted attention in some wellness and recovery communities, but important questions remain about their safety, efficacy, appropriate dosing, and clinical applications. The available evidence is not equivalent to the evidence supporting established treatments, and research findings cannot automatically be translated into proven benefits for people.
The company said these compounds would be considered for inclusion only when allowable. That qualification is significant because the regulatory status of each substance can determine whether and how it may be offered through a clinical service.
Company emphasizes its manufacturing and clinical infrastructure
Hims & Hers said its preparations for entering the peptide specialty have involved building infrastructure intended to support responsible access. The company cited investments in a U.S.-based peptide manufacturing facility, the development of dosing protocols with clinical experts, and frameworks for understanding the potential benefits and possible side effects of emerging treatments.
These efforts reflect the operational demands of entering a treatment category where product quality, clinical supervision, and the management of uncertainty are important considerations.
Manufacturing infrastructure can play a role in establishing consistent production processes and supporting quality controls. Nevertheless, the presence of a manufacturing facility does not independently establish the safety or effectiveness of a particular compound. The relevant standards, quality systems, testing procedures, and regulatory requirements remain essential.
Similarly, dosing protocols developed with clinical experts may help structure treatment decisions, but they need to be supported by appropriate evidence and updated as knowledge develops. Protocols for compounds with limited clinical data must account for uncertainty and avoid implying a level of certainty that research has not established.
The company said it has also developed frameworks to better understand both the possible benefits and potential side effects of the treatments it is exploring. Such monitoring can be an important component of responsible care, particularly when clinical experience and published research are still developing.
For patients and consumers, transparency about what is known and unknown can help establish realistic expectations. Clear information about treatment eligibility, potential risks, alternative options, and the limitations of available evidence is important when considering any emerging therapy.
Hims & Hers said it wants to build these considerations into the Peptides+ service rather than treating access as the only objective.
A cautious approach to emerging evidence
Although peptide therapies have generated substantial interest, Hims & Hers acknowledged that much of the knowledge surrounding some compounds remains preliminary. The company said published research is limited in several areas and that its understanding of these treatments draws in part on clinical experience accumulated over the past decade.
This acknowledgment is important because early research and clinical observations may help identify potential directions for further investigation, but they do not necessarily establish long-term safety or prove that a treatment is effective for a particular condition.
The strength of available evidence can vary considerably between compounds. Some substances have established medical uses in specific circumstances, while others have not undergone the same degree of rigorous human clinical evaluation. The route of administration, formulation, dose, duration of use, and characteristics of the patient population can also affect the relevance of research findings.
Consequently, a single conclusion cannot be applied to every compound described as a peptide or included in a peptide-focused wellness service.
Responsible clinical use requires healthcare professionals to distinguish between established indications, emerging evidence, and claims that remain unproven. It also requires a process for reassessing treatment decisions when new research or safety information becomes available.
Hims & Hers said provider-supervised treatment would form a central part of its approach. Independent healthcare providers are expected to assess eligible customers and prescribe personalized plans when appropriate, while licensed pharmacies will supply the treatments. The company also intends to provide ongoing clinical support.
This structure is designed to create a clearer distinction between professionally supervised care and products obtained through informal or unregulated channels. However, clinical oversight cannot eliminate all risks, and the safety of any treatment depends on the substance, its quality, the patient, and the circumstances of use.
The company said it intends to move carefully as it develops the specialty, placing responsible implementation ahead of rapid expansion.
Consumer demand highlights the importance of safeguards
Interest in peptides has expanded across wellness discussions, with consumers increasingly seeking options associated with energy, recovery, cognitive function, and healthy aging. This demand has also created challenges for healthcare providers and regulators who must assess the evidence behind emerging products and determine the conditions under which they may be used.
When consumers encounter products through informal markets, they may have difficulty determining whether the substance contains the stated ingredient, whether its preparation meets appropriate quality standards, or whether its proposed use is supported by reliable evidence.
These concerns help explain why regulated access, transparency, and clinical supervision are important parts of the debate.
At the same time, greater access should not be confused with a guarantee of benefit. Some consumers may be eligible for a particular treatment, while others may be better served by established therapies, lifestyle interventions, diagnostic evaluation, or no treatment at all. A healthcare professional’s assessment is therefore an important step in determining whether a proposed option is appropriate.
For companies operating in personalized healthcare, the challenge is to respond to consumer interest without overstating the science. Marketing language, treatment descriptions, and patient education materials need to reflect the strength of the available evidence and the limits of what is known.
Hims & Hers said it recognizes that some of the compounds under consideration hold promise while also acknowledging important gaps in current knowledge. The company intends to continue developing its approach as research and regulatory decisions progress.
Further regulatory review may shape the specialty’s development
The company also indicated that the FDA’s Pharmacy Compounding Advisory Committee is expected to consider five additional peptides at a future meeting. The outcome of that review could help inform the broader regulatory discussion surrounding the compounding of selected substances.
The PCAC provides recommendations on matters relating to pharmacy compounding. Its deliberations are one part of a wider regulatory process, and committee recommendations should not be mistaken for final authorization to market or compound a substance in every circumstance.
As the process continues, companies planning to offer peptide-related treatments will need to track the status of individual compounds and ensure their services comply with the requirements in force. Changes in policy or additional scientific information may affect product availability, treatment protocols, and the scope of services that can be provided.
Hims & Hers said it plans to continue refining Peptides+ as it learns more about these treatments and as the regulatory environment develops. The company has presented the specialty as a long-term effort to establish a responsible model for access rather than an attempt to move into the category as quickly as possible.
Customers can preview the planned service and join the interest list through the company’s websites for Hims Peptides+ and Hers Peptides+. Joining the list does not itself establish eligibility for treatment or guarantee access to any specific compound.
The planned introduction of Peptides+ places Hims & Hers within a developing segment of personalized healthcare that combines consumer interest, emerging scientific research, and evolving regulatory considerations.
The company aims to offer eligible customers a structured way to explore selected peptide-related therapies through independent provider assessment, individualized treatment plans, licensed pharmacy supply, and ongoing clinical support. Its planned lineup includes Sermorelin, Glutathione, vitamin B12, NAD+, and L-carnitine, with BPC-157 and TB-500 under consideration for a later stage when permitted.
The initiative also underscores the questions that will continue to shape this field: how to establish reliable evidence for emerging treatments, how to maintain consistent product quality, how to communicate uncertainty, and how to ensure that clinical decisions remain grounded in patient needs and applicable regulations.
Hims & Hers has emphasized that not everything about these compounds is currently understood. That uncertainty makes careful implementation, rather than speed alone, a central consideration as the company prepares for launch.
As regulatory review continues and further research becomes available, the company’s ability to maintain transparent standards and appropriately supervised care will be important to the development of Peptides+. The broader objective is to make emerging treatment options accessible where appropriate while recognizing that scientific validation, patient safety, and responsible prescribing must remain central to the process.
Source link: https://news.hims.com/
